Navigation Links
AMT Presents Positive Results of Phase I/II Study with Lead Product,at Annual Meeting of American Society of Gene Therapy

Efficacy and Safety of Gene Therapy in Lipoprotein Lipase Deficiency Established

Amsterdam, The Netherlands - May 31, 2007 - Amsterdam Molecular Therapeutics (AMT), a leader in the field of human gene therapy, reported positive Phase I/II clinical trial results with its lead product AMT-010 (now referred to as AMT-011) in Complete Lipoprotein Lipase (LPL) deficient patients at the 10th Annual Meeting of the American Society of Gene Therapy (ASGT) in Seattle. The study's lead investigator is Erik S.G. Stroes, MD, PhD, from the University of Amsterdam Medical Center in The Netherlands.

Ronald Lorijn, CEO of AMT, said, "We believe these excellent results may represent an important milestone for the entire field of gene therapy and for the many patients who today cannot be treated. Our clinical success and the breakthrough in our production platform place us squarely at the forefront of the gene therapy field that is finally coming into its own."

AMT's products rely on a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy to become a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.

Study design

The primary goal of the study presented at the ASGT was to investigate if AMT-010 reduces the elevated triglyceride (fat) levels and the associated risk of pancreatitis in Complete LPL deficient patients. The study design was an eight-patient open label dose-escalating study (low and mid dos
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:8/28/2008)...ir 11- and 12-year-olds from,meningitis, whooping ... ATLANTA, Aug 28 /PRNewswire-USNewswire/ -- The Ce...ational Center for Immunization and,Respiratory Di...ouncements,(PSAs) targeting the parents of pre-tee...he television and radio spots, part of CDC,s Pre-T...
(Date:8/27/2008)... Delaware, Montgomery,Philadelphia Counties, NOR...fter encouraging,results following the first night...ntal Protection will continue its efforts this eve...rne West Nile virus., Targeted aerial treatments ...n portions of Bucks, Delaware, Montgomery and Phil...
(Date:8/27/2008)...at The Children,s Hospital at, Montefiore Provid...and Specialty Services, ... Every Heart Condition, NEW YORK, Aug. 27 /PRNews...tefiore (CHAM) is bringing the medical miracle of ...owing the recent approval of its,transplant center...
(Date:8/26/2008)...fore Pharmaceuticals Inc.,presented data at the Se...,in Cancer in Washington, D.C., announcing the dis...hat demonstrate significant anticancer,activity in...lecular scaffold has been developed using,computat...kinase inhibitors,as well as isoform-selective sma...
Breaking Medicine Technology:DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 2DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 3Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 2Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 3Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 4Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3Respiratory illnesses and dog bites a concern for travelers to China for 2008 Olympics 24669 1Respiratory illnesses and dog bites a concern for travelers to China for 2008 Olympics 24669 2Geecf 3A Spectrum Blue Steel Announces Strategic Partnership with Al Manhal International Group of Abu Dhabi to Deploy Biosphere Facilities 6825 1Geecf 3A Spectrum Blue Steel Announces Strategic Partnership with Al Manhal International Group of Abu Dhabi to Deploy Biosphere Facilities 6825 2MTBC First Medical Billing Company in the U S To Offer Automated Real time Adjudication of Claims 24663 1MTBC First Medical Billing Company in the U S To Offer Automated Real time Adjudication of Claims 24663 2April Stewart Joins OrthoSynetics 28TM 29 as Corporate Communications Manager 24657 1
... Rexahn,Pharmaceuticals, Inc. (OTC BB:RXHN), a bio... development, and commercialization of,innovative ...rders,sexual dysfunction and other unmet medical ...ncipal Investigator of Phase I clinical,trial of t...n),will present results of the clinical study at ...
...n Transplantation, HORSHOLM, Denmark, May 31, 2007...ces positive Phase I clinical results for,its tran...nto US,Phase II clinical trials for organ transpla...nounces positive results,from its Phase I clinical...aily tacrolimus tablet. , A series of Phase I tria...
Other Medicine Technology:LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 2LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 3
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...sed on Monday, a drug that aims to prevent preterm...e earliest preterm births//, the main cause of dea...deza's (NASDAQ:ADZA) drug, Gestiva, is a long-acti...progesterone and is awaiting federal approval. ...
...rts have been restarted in India after declaring i... egg shipment to Muscat.// Due to the bird flu ou...ries around the world had stopped importing eggs f...t under control successfully by the several steps ...
...e of vaccination has yielded a much-improved quali...ing and help in fighting// many infectious disease...owever been slow and painstaking have been so bene...nd eradication of infectious diseases. It was unfo...
... balance in the body is skewed up is called Hypona... other conditions and requires urgent// treatment.... that some of the symptoms caused by hyponatremia ...a, vomiting, fatigue, and headache. Other serious ...
Other Medicine News:Health News:Gestiva – the pre-term birth drug probed by FD 2Health News:‘Bird flu-free’ India resumes egg expor 2Health News:Remarkable Progress In Development Of Vaccines 2Health News:Remarkable Progress In Development Of Vaccines 3Health News:Remarkable Progress In Development Of Vaccines 4
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
Medicine Products: